PATENT CLAIM ANALYSIS

Application Number: 16086408
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "256000"]

Abstract:
A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Claim (Index 3):
A compound as claimed in  claim 1  represented by formula (IIA) or an N-oxide thereof, or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , R f  and R g  are as defined in  claim 1 .

Metadata:
- Claim Count in Document: 14.0
- Percentile: 97.0
- Lexical Diversity: 1.52381
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15513357', '15101767', '15101798', '15580137', '15102003']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8004954588711997
- 35 USC 102 Novelty (BERT): 0.5530947088157974
- Combined Prediction Score: 0.7757553838656595
- Mean Citation Score: 402.34228999999993
- Max Citation Score: 409.78156
- Similarity Product: 302.04183207494737

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test